Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study
Tyrosine kinase 2 (TYK2) signaling has previously shown therapeutic potential in the treatment of psoriasis. The primary objective of this study was to assess the safety and tolerability of the TYK2 inhibitor PF-06826647. The area under the concentration-time curve over the dosing interval and the maximum concentration increased in a less than dose-proportional manner with increasing dose from 100 mg to 400 mg.
